Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2006

View Archived Issues

Aerosolized hydroxychloroquine studied in phase II for asthma

Bayer concludes divestment of antiinfectives research to Santo Holding

Orphan drug designation for SLIT Amikacin

American businesses of Sankyo and Daiichi to integrate

Immtech International changes name to Immtech Pharmaceuticals

Vertex and CFFT form new collaboration to develop VX-770 for cystic fibrosis

Samaritan concluding preclinical studies of SP-233 for Alzheimer's disease

Allergan completes acquisition of Inamed

Enrollment completed in phase III study of TH-9507 for HIV lipodystrophy

Phase III hepatorenal syndrome study of terlipressin completes enrollment

Schering AG supports Bayer offer

FDA Advisory Committee recommends against approval of Sparlon for ADHD

TBC-3711 on clinical hold following rat finding

Phase I/II study evaluates nimotuzumab for NSCLC

Idenix modifies phase IIb trials of valopicitabine

Phase II findings for ACP-103 for treatment-induced psychosis in Parkinson's

Orphan drug designation for Aastrom's Tissue Repair Cells in osteonecrosis

Spectrum to acquire oncology drug assets of Targent

Ranexa now available for chronic angina

Approvable letter for Thelin in PAH

In vivo efficacy of a novel CCR3 antagonist for allergic inflammatory disease

Avidex reports new immunomodulatory agents

Recent patents report new therapeutic agents for metabolic disorders

BMS-355249: novel potentiator of NT-3-mediated trk A and trk B activation

Novel LFA-1 antagonist demonstrates biological activity in vivo

Dipyridamole analogue potently inhibits ENT1

Spotlight on prostaglandin E2 EP1 receptors as mediators of neurotoxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...